European Commission Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 29, 2022 Novartis' Scemblix Nets European Approval for Subset of CML Patients Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 25, 2022 EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca Jul 25, 2022 Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jul 11, 2022 Legend Biotech Shutters Trial of CD4-Directed CAR T-Cell Therapy for T-Cell Lymphoma Jun 28, 2022 European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC May 24, 2022 European Commission Approves Keytruda in Early-Stage Triple-Negative Breast Cancer May 4, 2022 Novartis Nabs European Approval for Kymriah in Follicular Lymphoma Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 22, 2022 EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation Apr 5, 2022 Bristol Myers Squibb's Breyanzi Approved in Europe for Lymphoma Patients Apr 4, 2022 European Commission Approves Immunocore's T-Cell Receptor Therapy Kimmtrak in Uveal Melanoma Mar 28, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer